Clinical trial
Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP)…
NCT00315484 · Ortho Biotech Products, L.P., Industry · Completed
Key facts
| NCT number | NCT00315484 |
|---|---|
| Title | Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia |
| Official title | A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) To Evaluate Hematologic Response Rate In Anemic Cancer Patients Receiving Chemotherapy |
| Lead sponsor | Ortho Biotech Products, L.P., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Anemia, Chemotherapy |
| Intervention type | Drug |
| Interventions | Epoetin alfa and Darbepoetin alfa |
| Enrollment | 358 |
| Start date | Feb 1, 2003 |
| Completion | Oct 1, 2004 |
| First posted | Apr 18, 2006 |
| Last update posted | May 19, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: